<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05005520</url>
  </required_header>
  <id_info>
    <org_study_id>BB-CLIN-101</org_study_id>
    <nct_id>NCT05005520</nct_id>
  </id_info>
  <brief_title>Study of DTRI-031 in Healthy Volunteers</brief_title>
  <official_title>A Randomized, Double-Blind, Single-Center, Placebo-Controlled Phase 1 Study to Evaluate the Safety, Tolerability, PK and PD of Intravenous DTRI-031 in Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Basking Biosciences, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Basking Biosciences, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A randomized, double-blind, single center, placebo-controlled phase 1 study in healthy&#xD;
      volunteers to assess safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of&#xD;
      a single intravenous (iv) injection of DTRI-031&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Up to 5 cohorts of 8 healthy volunteers for a total of 40 volunteers will be randomized to&#xD;
      either DTRI-031 or matching placebo (6 active:2 placebo). Two sentinel subjects, one&#xD;
      randomized to each group, will be dosed at least 1 day prior to dosing of the remaining&#xD;
      subjects in a cohort.&#xD;
&#xD;
      Subjects will complete a screening visit up to 28 days prior to administration of study drug&#xD;
      to confirm eligibility. Eligible subjects will arrive at the phase 1 unit up to 24 hours&#xD;
      prior to Day 1 and remain until completion of 24-hour assessments. Subjects will return for a&#xD;
      Day 7 follow-up visit and receive a safety assessment telephone call on Day 28.&#xD;
&#xD;
      A Safety Review Committee will review individual subject and aggregate group safety data&#xD;
      following each dose-based study cohort and recommend whether the trial should continue to the&#xD;
      next cohort.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 20, 2021</start_date>
  <completion_date type="Anticipated">January 2022</completion_date>
  <primary_completion_date type="Anticipated">January 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Randomized, placebo-controlled, double-blinded, dose escalation to evaluate the safety, PK, and PD of a single dose of investigational drug or placebo</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
    <masking_description>Double blinded, placebo-controlled</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Safety as assessed by adverse events (AEs)</measure>
    <time_frame>From dosing (DTRI-031 or placebo) to final visit (Day 28)</time_frame>
    <description>Incidence of treatment-emergent AEs</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics as measured by DTRI-031 plasma levels</measure>
    <time_frame>From dosing to 24 hours after dosing</time_frame>
    <description>Plasma concentration of DTRI-031 (after single dose of drug)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma von Willebrand Factor (vWF) levels</measure>
    <time_frame>From dosing to 24 hours after dosing</time_frame>
    <description>Level of vWF following single administration of drug</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Platelet Function</measure>
    <time_frame>From dosing to 24 hours after dosing</time_frame>
    <description>Whole blood platelet function closure times</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Healthy Volunteers</condition>
  <condition>Pharmacokinetics</condition>
  <condition>Pharmacodynamics</condition>
  <arm_group>
    <arm_group_label>Active Comparator: Single ascending dose DTRI-031</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Drug: DTRI-031 Single doses of DTRI-031 delivered via intravenous injection. Ascending dose levels will be evaluated.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo Comparator: Single Dose Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Drug: Placebo Single doses of placebo delivered via intravenous injection, matched to DTRI-031 cohorts</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DTRI-031</intervention_name>
    <description>Investigational drug</description>
    <arm_group_label>Active Comparator: Single ascending dose DTRI-031</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Matching placebo to DTRI-031</description>
    <arm_group_label>Placebo Comparator: Single Dose Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  18-55 years of age&#xD;
&#xD;
          -  Ability to provide written consent&#xD;
&#xD;
          -  Weight 50-110 kg with BMI 18.5-32 kg/m2&#xD;
&#xD;
          -  Willingness to use contraceptives&#xD;
&#xD;
          -  Negative COVID-19 test&#xD;
&#xD;
          -  Negative results for alcohol and drugs of abuse&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pregnant or lactating females&#xD;
&#xD;
          -  Familial bleeding disorder or individual or family history of bleeding diathesis or&#xD;
             coagulopathy&#xD;
&#xD;
          -  Females with active menstruation on day of dosing&#xD;
&#xD;
          -  Use of prescription medications known to affect platelet function&#xD;
&#xD;
          -  Use of NSAIDs, aspirin, anti-platelet or anti-coagulation therapy within 10 days of&#xD;
             dosing&#xD;
&#xD;
          -  Contraindication to anticoagulation or increased bleeding risks&#xD;
&#xD;
          -  History of thrombocytosis, high platelet count, intracranial bleeding, aneurysm,&#xD;
             stroke, vascular disease&#xD;
&#xD;
          -  History of peptic ulcer disease, gastrointestinal or genitourinary bleed, severe&#xD;
             trauma, fracture, major surgery of biopsy of parenchymal organ within past 3 months&#xD;
&#xD;
          -  Planned surgery during the study&#xD;
&#xD;
          -  Any clinical significant abnormality at screening&#xD;
&#xD;
          -  Use of investigational drug in past 30 days or 5 half lives&#xD;
&#xD;
          -  Concurrent enrollment in another clinical study or more than 3 clinical studies in&#xD;
             past 12 months&#xD;
&#xD;
          -  Any prior history of substance abuse or treatment or positive urine screen for drugs&#xD;
             of abuse or positive breathalyzer test&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Nucleus Network</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <zip>3004</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Research Coordinator</last_name>
      <phone>+61 478 658 628</phone>
      <email>k.riddell@nucleusnetwork.com.au</email>
    </contact>
    <investigator>
      <last_name>Jason Lickliter, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Australia</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>August 9, 2021</study_first_submitted>
  <study_first_submitted_qc>August 12, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 13, 2021</study_first_posted>
  <last_update_submitted>October 28, 2021</last_update_submitted>
  <last_update_submitted_qc>October 28, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

